Table 1.

Characteristics of study subjects (n = 93) stratified by N-BP exposure and the occurrence of bisphosphonate-associated osteonecrosis of the jaw (ONJ)

Group	N	Mean age (years ± SD)	Median length of time on N-BP therapy (days, range)	Characteristics and type of N-BP therapy
N-BP treatment naïve controls	26	66.4 ± 10.0	NA	18 with osteoporosis (mean age 72.1 ± 6)
				8 Postmenopausal women without osteoporosis (mean age 53.6 ± 2)
Oral N-BP	30	74.1 ± 5.7	90 (1,764)	90% On oral alendronate (70 mg/week); 10% on oral ibandronate (150 mg/months)
Intravenous N-BP	31	73.2 ± 5.5	813 (1,982)	All on intravenous ibandronate (3 mg/months)
ONJ	6	61.3 ± 12.5	1,113 (1,282)	1 Woman (85 yrs) was being treated with 5 mg/year intravenous zoledronate (had received 2 shots) for osteoporosis, previously had a blood malignancy and was on prednisone
				1 Woman on systemic corticosteroids and mycophenolate mofetil on oral aledronate (70 mg/week) for 3.5 years
				1 Woman on interferon therapy for hepatitis B & C on oral aledronate (70 mg/week) for 5 years
				3 Women who had been treated for metastatic breast cancer; all on 4 mg/months intravenous zoledronate (from 1.4 to 2.8 years)